Literature DB >> 8228341

Immunologic parameters 2 years after high-titer measles immunization in Peruvian children.

M E León1, B Ward, R Kanashiro, H Hernández, S Berry, A Vaisberg, J Escamilla, M Campos, S Bellomo, V Azabache.   

Abstract

Immunization with high-titer measles vaccines has been associated with excess mortality in children 2-4 years after vaccination. In this study, immunologic parameters in 64 Peruvian children who had been immunized an average of 27 months earlier with high-titer vaccines were compared with parameters in 76 recipients of low-titer vaccines. Delayed-type hypersensitivity, lymphocyte phenotype distributions by flow cytometry, and lymphoproliferation after phytohemagglutinin (PHA) stimulation were assessed. High-titer recipients had smaller indurations to tetanus, diphtheria, and Proteus (P < .05) antigens, decreased PHA stimulation (P = .04), and a lower percentage of CD4+ lymphocytes (P = .04) than low-titer recipients. After adjustment for sex, concurrent illnesses, and other variables in regression analyses, high-titer recipients had a lower percentage of CD4+ lymphocytes (P = .025) and decreased lymphocyte proliferation to PHA (P = .058). These results may provide a clue to the pathogenesis of delayed excess mortality after high-titer measles vaccination in some developing countries.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8228341     DOI: 10.1093/infdis/168.5.1097

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  8 in total

1.  Modulation of immune system function by measles virus infection: role of soluble factor and direct infection.

Authors:  R S Fujinami; X Sun; J M Howell; J C Jenkin; J B Burns
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

2.  Sex-associated differences in the antibody-dependent cellular cytotoxicity antibody response to measles vaccines.

Authors:  S Atabani; G Landucci; M W Steward; H Whittle; J G Tilles; D N Forthal
Journal:  Clin Diagn Lab Immunol       Date:  2000-01

3.  Cell mediated immunity after measles in Guinea-Bissau: historical cohort study.

Authors:  S O Shaheen; P Aaby; A J Hall; D J Barker; C B Heyes; A W Shiell; A Goudiaby
Journal:  BMJ       Date:  1996-10-19

4.  Long-term safety and serologic response to measles, mumps, and rubella vaccination in HIV-1 infected adults.

Authors:  Benjamin M Stermole; Greg A Grandits; Mollie P Roediger; Brychan M Clark; Anuradha Ganesan; Amy C Weintrob; Nancy F Crum-Cianflone; Tomas M Ferguson; Grace E Macalino; Michael L Landrum
Journal:  Vaccine       Date:  2011-02-23       Impact factor: 3.641

Review 5.  Use of licensed vaccines for active immunization of the immunocompromised host.

Authors:  L A Pirofski; A Casadevall
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

6.  Decreased CD4 and increased CD8 counts with T cell activation is associated with chronic helminth infection.

Authors:  A Kalinkovich; Z Weisman; Z Greenberg; J Nahmias; S Eitan; M Stein; Z Bentwich
Journal:  Clin Exp Immunol       Date:  1998-12       Impact factor: 4.330

7.  Evidence that measles virus hemagglutinin initiates modulation of leukocyte function-associated antigen 1 expression.

Authors:  A R Nagendra; C W Smith; P R Wyde
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

Review 8.  Virus-Induced T Cell-Mediated Heterologous Immunity and Vaccine Development.

Authors:  Kathrin Balz; Lilith Trassl; Valerie Härtel; Philipp P Nelson; Chrysanthi Skevaki
Journal:  Front Immunol       Date:  2020-03-31       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.